New Anti-Seizure Medication Transforms Lives of Children With Epileptic Encephalopathy

What Are Developmental and Epileptic Encephalopathies?

Developmental and epileptic encephalopathies (DEEs) represent some of the most challenging forms of childhood epilepsy. Conditions such as Dravet syndrome, Lennox-Gastaut syndrome, and CDKL5 deficiency disorder are characterised by frequent, difficult-to-control seizures that begin in infancy or early childhood. The International League Against Epilepsy (ILAE) classifies these conditions as disorders where the epileptic activity itself contributes to developmental slowing or regression beyond what would be expected from the underlying cause alone.

Children with DEEs often experience multiple seizure types — including tonic-clonic, absence, and drop seizures — sometimes dozens per day. Standard anti-seizure medications frequently prove insufficient, and many patients require combinations of three or more drugs with limited benefit. The impact extends far beyond seizures: families describe restricted daily activities, constant vigilance, and significant emotional strain. According to the Epilepsy Foundation, roughly one-third of all epilepsy patients have drug-resistant forms, with DEEs representing a disproportionate share of this treatment-resistant population.

How Are New Targeted Therapies Changing Outcomes for Children?

The treatment landscape for severe paediatric epilepsies has shifted markedly in recent years. Rather than relying solely on broad-spectrum anti-seizure medications, researchers have developed therapies targeting specific molecular pathways involved in individual DEE subtypes. Fenfluramine (marketed as Fintepla), originally approved for Dravet syndrome, works through serotonin receptor modulation and has demonstrated sustained seizure reduction in clinical trials published in The Lancet Neurology. Ganaxolone, a neurosteroid targeting GABA-A receptors, received FDA approval for seizures associated with CDKL5 deficiency disorder.

Parents and clinicians report that the benefits extend well beyond seizure counts. Families describe children who can attend school more regularly, engage in play, and achieve developmental milestones that previously seemed out of reach. A BBC report highlighted parents stating their children could now "enjoy life" following treatment with newer agents — a testament to how reducing seizure burden translates into tangible daily improvements. The European Medicines Agency (EMA) and the FDA have both introduced expedited pathways for rare paediatric epilepsy treatments, reflecting the urgent unmet need in this population.

What Should Families Know About Accessing These Treatments?

Access to newer anti-seizure therapies typically requires evaluation at a specialist paediatric epilepsy centre. Genetic testing has become an increasingly important step, as many of the targeted treatments are indicated for specific genetic subtypes of DEE. The ILAE recommends genetic testing for all children with early-onset epilepsy of unknown cause, as identifying the underlying mutation can open doors to syndrome-specific treatments and clinical trials.

For families in regions where specific drugs are not yet approved or reimbursed, clinical trials and compassionate use programmes may offer alternative pathways. Organisations such as the Dravet Syndrome Foundation and CDKL5 UK provide resources for connecting families with research centres. Clinicians emphasise that while these new therapies represent genuine progress, they are not cures — ongoing monitoring, dose adjustment, and multidisciplinary support remain essential components of care.